ZyVersa Therapeutics
ZVSA
ZVSA was delisted on the 16th of July, 2025.
29 hedge funds and large institutions have $73.3M invested in ZyVersa Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
34,111% more capital inflows, than outflows
Capital inflows: $10.7M | Capital outflows: $31.4K
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
21% more funds holding
Funds holding: 24 → 29 (+5)
13.28% more ownership
Funds ownership: 77.41% → 90.69% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$5.52M |
| 2 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$2.74M |
| 3 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.97M |
| 4 |
OFG
OTA Financial Group
Purchase,
New York
|
+$290K |
| 5 |
Saba Capital Management
New York
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wolverine Asset Management
Chicago,
Illinois
|
-$31.4K |
ZVSA Hedge Fund Activity: Q3 2022 in Review
29 of the 5,831 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q3 2022, worth a combined $73.3M — up 18% from $62.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ZVSA positions and 0 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Yakira Capital Management, opening a new position worth an estimated $5.52M. The largest seller was Wolverine Asset Management, cutting an estimated $31.4K.
- 29 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q3 2022, up from 24 in Q2 2022.
- Funds reported $73.3M of ZyVersa Therapeutics stock for Q3 2022, up 18% quarter-over-quarter.
- 5 funds opened new ZyVersa Therapeutics positions in Q3 2022 and 0 closed out, a net change of +5 holders.
- The largest ZyVersa Therapeutics buyer in Q3 2022 was Yakira Capital Management, an estimated $5.52M added.
- The largest ZyVersa Therapeutics seller in Q3 2022 was Wolverine Asset Management, an estimated $31.4K sold.
Based on aggregated 13F filings for Q3 2022.